Giffin Brett A.'s Form 4 filing
T2 Biosystems, Inc. (TTOO) · filed Nov 22, 2022
- Accession no.
- 0000899243-22-036695
- Filed
- Nov 22, 2022
- Trade date
- Nov 8-10, 2022
- Filing delay
- 14 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.31K. It was filed 14 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Giffin Brett A.CIK 0001892921 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 8, 2022 | Common Stock | MOption exerciseAcquired | +3,333 | –F1 | – | 3,545 | Direct | |
| Nov 10, 2022 | Common Stock | SSaleDisposed | −1,292 | $1.79 | −$2,312.68 | 2,253 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 8, 2022 | Common Stock | MOption exerciseDisposed | −3,333 | $0.00 | $0 | 6,667 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Referenced by the price of 1 transaction in Table I.